#### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization

International Bureau



# 

# (10) International Publication Number WO 2010/062451 A1

# (43) International Publication Date 3 June 2010 (03.06.2010)

(51) International Patent Classification:

 A61B 5/053 (2006.01)
 A61N 1/372 (2006.01)

 G01R 27/02 (2006.01)
 A61N 1/39 (2006.01)

 H03F 3/00 (2006.01)
 A61N 1/365 (2006.01)

A61B 5/026 (2006.01)

(21) International Application Number:

PCT/US2009/058127

(22) International Filing Date:

24 September 2009 (24.09.2009)

(25) Filing Language:

English

(26) Publication Language:

English

US

(30) Priority Data:


12/263,346 31 October 2008 (31.10.2008)

(71) Applicant (for all designated States except US): MEDTRONIC, INC. [US/US]; 710 Medtronic Parkway, MS LC340, Minneapolis, Minnesota 55432 (US). (72) Inventors; and

- (75) Inventors/Applicants (for US only): WHALSTRAND, John, D. [US/US]; 685 Lake Pine Drive, Shoreview, Minnesota 55126 (US). DENISON, Timothy, J. [US/US]; 4441 Beard Avenue South, Minneapolis, Minnesota 55410 (US). SANTA, Wesley, A. [US/US]; 3360 139th Lane Northwest, Andover, Minnesota 55304 (US).
- (74) Agents: SOLDNER, Michael, C. et al.; 710 Medtronic Parkway, MS LC340, Minneapolis, Minnesota 55432 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

#### (54) Title: DETERMINING INTERCARDIAC IMPEDANCE



(57) Abstract: A system and method for determining complex intercardiac impedance to detect various cardiac functions are disclosed involving a signal generator means for providing an adjustable direct current signal, a modulator for modulating the adjustable direct current signal to produce a modulated signal, at least one electrode for propagating the modulated signal across a myocardium, at least one sensor for detecting an outputted modulated signal from the myocardium, and at least one circuit to reduce the influence of process noise (aggressors) in the outputted modulated signal. The at least one circuit comprises an amplifier, a demodulator, and an integrator. The amplitude and phase of the final outputted modulated signal indicate the complex impedance of the myocardium. Changes in the complex impedance patterns of the myocardium provide indication of reduced oxygen and blood flow to the myocardium. The apparatus can be employed in implantable devices, including cardiac pacemakers and implantable cardioverter defibrillators.



(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

— with international search report (Art. 21(3))

#### **DETERMINING INTERCARDIAC IMPEDANCE**

#### **Background of the Disclosure**

The present disclosure relates to determining intercardiac impedance. In particular, it relates to determining complex intercardiac impedance to detect various cardiac functions.

### **Summary of the Disclosure**

The present disclosure relates to an apparatus, system, and method for determining intercardiac impedance to detect various cardiac functions. In one or more embodiments, the method for determining complex intercardiac impedance involves providing an adjustable direct current signal, modulating the adjustable direct current signal to produce a modulated signal, propagating the modulated signal across a myocardium, detecting an outputted modulated signal from the myocardium, and using at least one circuit to reduce the influence of process noise (aggressors) in the outputted modulated signal.

In one or more embodiments, the at least one circuit performs the steps comprising amplifying the outputted modulated signal to produce a second outputted modulated signal, wherein the second outputted modulated signal has a signal of interest that is amplified at a higher frequency than the process noise (aggressors); demodulating the second outputted modulated signal to produce a third outputted modulated signal, wherein the third outputted modulated signal has the signal of interest demodulated to a lower frequency and the process noise (aggressors) becomes modulated to a higher frequency; and passing the third outputted modulated signal through an integrator to produce a fourth outputted modulated signal, wherein the fourth outputted modulated signal has the signal of interest retained and the process noise (aggressors) filtered out.

In one or more embodiments, the amplitude and phase of the fourth outputted modulated signal indicate the complex impedance of the myocardium. In addition, changes in the complex impedance patterns of the myocardium provide indication of various cardiac functions and an ischemic event. Also, changes in patterns sensed by a combination of correlated sensors for specific regions of the heart provide indication of various cardiac functions and an ischemic event.

15

10

5

20

25

10

15

20

25

30

PCT/US2009/058127

In one or more embodiments, the direct current signal is adjustable. Additionally, in some embodiments, the modulated signal has a nominal frequency of approximately 4 kilohertz to prevent interference with functions of other implanted devices.

In one or more embodiments, the method for determining intercardiac impedance may further comprise the steps of generating a signal when an ischemic event is indicated, where the signal contains an alert message; and transmitting the signal.

In one or more embodiments, the apparatus, system, and/or method is employed with at least one implantable medical device (IMD). In some embodiments, the at least one implantable medical device (IMD) is a cardiac pacemaker. In other embodiments, the at least one implantable medical device (IMD) is an implantable cardioverter defibrillator (ICD).

In one or more embodiments, a system is used for determining intercardiac impedance. The system comprises a signal generator for providing an adjustable direct current signal, a modulator for modulating the adjustable direct current signal to produce a modulated signal, at least one electrode for propagating the modulated signal across a myocardium, at least one sensor for detecting an outputted modulated signal from the myocardium; and at least one circuit to reduce the influence of process noise (aggressors) in the outputted modulated signal.

In one or more embodiments, at least one circuit comprises an amplifier for amplifying the outputted modulated signal to produce a second outputted modulated signal, wherein the second outputted modulated signal has a signal of interest that is amplified at a higher frequency than the process noise (aggressors); a demodulator for demodulating the second outputted modulated signal to produce a third outputted modulated signal, wherein the third outputted modulated signal has the signal of interest demodulated to a lower frequency and the process noise (aggressors) becomes modulated to a higher frequency; and an integrator for passing the third outputted modulated signal through to produce a fourth outputted modulated signal, wherein the fourth outputted modulated signal has the signal of interest retained and the process noise (aggressors) filtered out, wherein the amplitude and phase of the fourth outputted modulated signal indicate the complex impedance of the myocardium.

10

15

20

25

30

In one or more embodiments, at least one electrode is a left ventricular tip (LVTIP) electrode, and the at least one sensor is a right ventricular coil (RVCOIL) sensor. In some embodiments, the at least one electrode is a left ventricular tip (LVTIP) electrode, and the at least one sensor is a right ventricular ring (RVRING) sensor. In other embodiments, the at least one electrode is a right ventricular tip (RVTIP) electrode, and the at least one sensor is a right ventricular ring (RVRING) sensor. In some embodiments, the at least one electrode is a left ventricular tip (LVTIP) electrode, and the at least one sensor is a left superior vena cava coil (SVCCOIL) sensor. In other embodiments, the at least one electrode is a right ventricular tip (RVTIP) electrode, and the at least one sensor is a superior vena cava coil (SVCCOIL) sensor.

In one or more embodiments, the system for determining intercardiac impedance may further comprise a signal generator for generating a signal when an ischemic event is indicated, where the signal contains an alert message; and a transmitter for transmitting the signal.

In one or more embodiments, a system is used for determining intercardiac impedance. The system comprises a signal generator means for providing an adjustable direct current signal; a modulator means for modulating the adjustable direct current signal to produce a modulated signal; at least one electrode means for propagating the modulated signal across a myocardium; at least one sensor means for detecting an outputted modulated signal from the myocardium; and at least one circuit means for reducing the influence of process noise (aggressors) in the outputted modulated signal.

In one or more embodiments, the at least one circuit means comprises an amplifier means for amplifying the outputted modulated signal to produce a second outputted modulated signal has a signal of interest that is amplified at a higher frequency than the process noise (aggressors); a demodulator means for demodulating the second outputted modulated signal to produce a third outputted modulated signal has the signal of interest demodulated to a lower frequency and the process noise (aggressors) becomes modulated to a higher frequency; and an integrator means for passing the third outputted modulated signal through to produce a fourth outputted modulated signal, wherein the fourth outputted modulated signal has the signal of interest retained and the process noise

(aggressors) filtered out, wherein amplitude and phase of the fourth outputted modulated signal indicate the complex impedance of the myocardium.

In one or more embodiments, the system for determining intercardiac impedance may further comprise a signal generator means for generating a signal when an ischemic event is indicated, where the signal contains an alert message; and a transmitter means for transmitting the signal.

## **Brief Description of the Drawings**

These and other features, aspects, and advantages of the present disclosure will become better understood with regard to the following description, appended claims, and accompanying drawings where:

- FIG. 1 is an illustration of a myocardium containing sensors for determining intercardiac impedance in accordance with at least one embodiment of the present disclosure.
- FIG. 2 is a schematic circuit diagram for determining intercardiac impedance in accordance with at least one embodiment of the present disclosure.
- FIG. 3 is a graphical representation of the stimulation current (Istim) in the time domain in accordance with at least one embodiment of the present disclosure.
- FIG. 4 is a graphical representation of modulated signal V1 in the time domain in accordance with at least one embodiment of the present disclosure.
- FIG. 5 is a graphical representation of outputted modulated signal V2 in the time domain in accordance with at least one embodiment of the present disclosure.
- FIG. 6 is a graphical representation of outputted modulated signal VA in the time domain in accordance with at least one embodiment of the present disclosure.
- FIG. 7 is a graphical representation of outputted modulated signal VA' in the time domain in accordance with at least one embodiment of the present disclosure.
- FIG. 8 is a graphical representation of outputted modulated signal VB in the time domain in accordance with at least one embodiment of the present disclosure.
- FIG. 9 is a graphical representation of outputted modulated signal Vout in the time domain in accordance with at least one embodiment of the present disclosure.
- FIG. 10 is a graphical representation of the stimulation current (Istim) in the frequency domain in accordance with at least one embodiment of the present disclosure.

5

10

15

20

25

10

15

20

25

30

FIG. 11 is a graphical representation of modulated signal V1 in the frequency domain in accordance with at least one embodiment of the present disclosure.

FIG. 12 is a graphical representation of outputted modulated signal V2 in the frequency domain in accordance with at least one embodiment of the present disclosure.

FIG. 13 is a graphical representation of outputted modulated signal VA in the frequency domain in accordance with at least one embodiment of the present disclosure.

FIG. 14 is a graphical representation of outputted modulated signal VA' in the frequency domain in accordance with at least one embodiment of the present disclosure.

FIG. 15 is a graphical representation of outputted modulated signal VB in the frequency domain in accordance with at least one embodiment of the present disclosure.

FIG. 16 is a graphical representation of outputted modulated signal Vout in the frequency domain in accordance with at least one embodiment of the present disclosure.

### **Detailed Description**

The methods and apparatus disclosed herein provide an operative system for determining intercardiac impedance. Specifically, this system allows for determining complex intercardiac impedance to detect various cardiac functions including, but not limited to, contractility, capture detection, atrium-ventricle optimization, right ventricular function, left ventricular function, cardiac output (stroke volume), and right to left ventricular synchronization. In addition, this system allows for the monitoring of complex intercardiac impedance for the detection of ischemia, which is related to myocardial tissue viability. Ischemia is an absolute or relative shortage of blood supply to an organ, which causes tissue damage because of the lack of oxygen and nutrients to the affected tissue.

The present disclosure describes a system comprising an implantable medical device (IMD) that includes an intercardiac impedance measurement circuit. Implantable medical devices (IMDs) are devices that are designed to be implanted into a patient. Examples of implantable medical devices to be utilized with this system include, but are not limited to, cardiac pacemakers, implantable cardioverter defibrillators (ICDs), and other devices that include a combination of pacing and defibrillation including cardiac resynchronization therapy. These implantable devices are typically used to treat patients using electrical therapy. In addition, these devices may include electrical leads connected to sensors located on the myocardium that are used to monitor electrical signals.

10

15

20

25

30

The intercardiac impedance measurement circuit employed by this system is adapted to be coupled to implantable electrodes/sensors in order to obtain an intercardiac impedance signal between the electrodes/sensors. The amplitude and phase of the intercardiac impedance signal indicate the complex impedance of the myocardium. The complex impedance of the myocardium can be used to detect various cardiac functions.

The complex impedance of the myocardium typically fluctuates in a corresponding pattern with the beating of the heart. Changes in the complex impedance patterns of the myocardium can indicate reduced oxygen and blood flow to the myocardium and, thus, provide a method for an immediate indication of an acute ischemic event (acute myocardial infarction (AMI)). The system of the present disclosure monitors the impedance of the heart and, thus, is able to detect possible ischemia of the myocardium. In addition, changes in the patterns sensed by a combination of correlated sensors for specific regions of the heart may provide indication of various cardiac functions and/or an ischemic event. In the event that an ischemic event is detected, the system may cause a signal, which is carrying an alert message, to be generated and transmitted directly to the patient or sent through telemetry links to a monitoring receiver. Various telemetry methods and systems may be employed by the system of the present disclosure.

In the following description, numerous details are set forth in order to provide a more thorough description of the system. It will be apparent, however, to one skilled in the art, that the disclosed system may be practiced without these specific details. In the other instances, well known features have not been described in detail so as not to unnecessarily obscure the system.

FIG. 1 contains an illustration of a myocardium 110 containing electrodes and/or sensors for determining intercardiac impedance in accordance with at least one embodiment of the present disclosure. In this illustration, a human heart 110 is depicted as having electrodes and/or sensors (130, 135, 140, 145, 150, 155, 160, and 165) located at various points on the myocardium 110.

Also depicted in this figure is an implantable medical device (IMD) 100 that is in electrical communication with a patient's heart 110 by the use of at least three electrical leads (115, 120, and 125). Right ventricular lead 115 has at least a superior vena cava (SVC) coil electrode/sensor 130, a right ventricular coil (RVCOIL) electrode/sensor 140, a

10

15

20

25

30

right ventricular ring (RVRING) electrode/sensor 145, and/or a right ventricular tip (RVTIP) electrode/sensor 150. In addition, right atrial lead 120 has at least a right atrial tip (RATIP) electrode/sensor 135 and/or a right atrial ring (RARING) electrode/sensor 170. Additionally, coronary sinus lead 125 has at least a left ventricular tip (LVTIP) electrode/sensor 165, multiple left ventricular (LV) electrodes/sensors (not shown in figure), a left atrial ring (LARING) electrode/sensor, and/or a left atrial coil (LACOIL) electrode/sensor.

In one or more embodiments, the system of the present disclosure is able to obtain an intercardiac impedance signal between at least one electrode and at least one sensor. In at least one embodiment, a right ventricle coil (RVCOIL) sensor 140 may detect an impedance signal that originated from left ventricle tip (LVTIP) electrode 165. In some embodiments, a right ventricular ring (RVRING) sensor 145 may detect an impedance signal that originated from the left ventricle tip (LVTIP) electrode 165. In one or more embodiments, a right ventricular ring (RVRING) sensor 145 may detect an impedance signal that originated from the right ventricular tip (RVTIP) electrode 150. These three specific signal paths each indicate an impedance signal that is proportional to blood flow, and provide a first derivative that is an indication of cardiac contractility. In addition, a change in complex impedance pattern for any of these particular signal paths can indicate that the portion of the heart the path crosses has been affected by ischemia. Thus, the various combinations of electrodes and sensors that are employed by this system provide comprehensive vector coverage of the heart.

In one or more embodiments, the disclosed system allows for determining intercardiac impedance to detect various cardiac functions including, but not limited to, contractility, capture detection, atrium-ventricle optimization, right ventricular function, left ventricular function, cardiac output (stroke volume), and right to left ventricular synchronization. A single impedance signal path can indicate various cardiac functions as well as the presence of ischemia of the corresponding region of the heart 110 that the signal path crosses.

In one or more embodiments, for example, an impedance signal path from a right ventricular tip (RVTIP) electrode 150 to a superior vena cava coil (SVCCOIL) sensor 130 can detect various cardiac functions of the right side of the heart 110. In another example,

10

15

20

25

30

an impedance signal path from a right atrial tip (RATIP) electrode 135 to the superior vena cava coil (SVCCOIL) sensor 130 can also detect various cardiac functions of the right side of the myocardium 110. In an additional example, an impedance signal path from a left ventricular tip (LVTIP) electrode 165 to a superior vena cava coil (SVCCOIL) sensor 130 can detect various cardiac functions of the left side of the heart 110. In yet another example, an impedance signal patch from a right atrial ring (RARING) electrode 160 to a superior vena cava coil (SVCCOIL) sensor 130 can detect various cardiac functions of the left side of the heart 110.

In other embodiments of this system, the system may employ more or less electrodes and/or sensors than are illustrated in FIG. 1. Also, in alternative embodiments, electrodes and/or sensors may be placed at other locations of the myocardium 110 than are shown in the FIG. 1.

FIG. 2 contains a schematic circuit diagram 200 for determining intercardiac impedance in accordance with at least one embodiment of the present disclosure. In this figure, a stimulation current (Istim), which is a direct current (DC) signal, is first generated. The stimulation current (Istim) is adjustable. In one or more embodiments, the stimulation current (Istim) is adjustable at discrete values between approximately 500 nano amperes and approximately 10 micro amperes. In alternative embodiments, the stimulation current (Istim) may be adjustable at various other ranges. The current is generated by switching a programmable resistor in series with a supply. Alternatively, the stimulation current (Istim) may be generated by other means including, but not limited to, various signal generators.

The stimulation current (Istim) is then modulated 220 at a nominal frequency of approximately 4 kilohertz (KHz) by a modulator 250 to produce modulated signal V1. The nominal frequency of approximately 4 KHz prevents interference with functions of other implanted devices. The modulation of the stimulation current (Istim) allows for the stimulation and measurement circuitry to be isolated from the direct current (DC) potentials on the lead pathway. In alternative embodiments, the signal is modulated at various other frequencies. In one or more embodiments of this system, the signal is modulated into a square wave. However, in alternative embodiments, the signal can be modulated into, but not limited to, a sinusoid, or pulses.

10

15

20

25

30

The modulated signal V1 is then propagated from at least one electrode located on the myocardium through the myocardium 210. At least one sensor located on the myocardium 210 senses the outputted modulated signal V2. The outputted modulated signal V2 is combined with process noise (aggressors) 230. The resultant signal that contains the impedance signal of the heart with process noise (aggressors) 230 is outputted modulated signal VA. The resultant outputted modulated signal VA is then passed through at least one circuit 290 to reduce the influence of process noise (aggressors) 230 in the outputted modulated signal VA.

In the at least one circuit 290, the outputted modulated signal VA is amplified through an amplifier 240 to produce outputted modulated signal VA'. Outputted modulated signal VA' has a signal of interest that is amplified at a higher frequency than the process noise (aggressors) 230 within the signal. Outputted modulated signal VA' is then demodulated 280 by demodulator 250 to produce outputted modulated signal VB. Outputted modulated signal VB has a signal of interest that is demodulated to a lower frequency and its process noise (aggressors) 230 becomes modulated to a higher frequency.

In one or more embodiments, a feedback loop 270 is employed to reduce errors that result from the low bandwidth of the amplifier 240 and to set the gain. In the circuit, outputted modulated signal VB is passed through an integrator 260 to produce outputted modulated signal Vout. The integrator 260 stabilizes the feedback loop 270 and acts as a low pass filter. In one or more embodiments of the system, an additional resistor-capacitor (RC) low pass filter is included at the output of the at least one circuit 290 to further isolate the signal of interest.

The resultant signal of interest of the outputted modulated signal Vout indicates the impedance of the area of the myocardium that the signal passed through. If demodulator 250 is clocked in phase with the simulation current (Istim), the real impedance is measured from outputted modulated signal Vout. Alternatively, if the demodulator 250 is clocked at -90 degrees with respect to the stimulation current (Istim), the imaginary part of the impedance is measured from the outputted modulated signal Vout.

FIG. 3 contains a graphical representation of the stimulation current (Istim) in the time domain in accordance with at least one embodiment of the present disclosure. In this

10

15

20

25

30

figure, the stimulation current (Istim) is depicted as a direct current (DC) signal. FIG. 4 illustrates a graphical representation of modulated signal V1 in the time domain in accordance with at least one embodiment of the present disclosure. In this figure, the stimulation current (Istim) is shown to have been modulated at approximately 4 kHz into a square wave.

FIG. 5 illustrates a graphical representation of outputted modulated signal V2 in the time domain in accordance with at least one embodiment of the present disclosure. In this figure, the reactive outputted modulated signal V2 is depicted has having a shift in phase versus FIG. 4. The amount of shift in phase of the signal is related to the amount of the reactive component of the impedance of the signal.

FIG. 6 is a graphical representation of outputted modulated signal VA in the time domain in accordance with at least one embodiment of the present disclosure. In this figure, the outputted modulated signal VA includes process noise (aggressors).

FIG. 7 shows a graphical representation of outputted modulated signal VA' in the time domain in accordance with at least one embodiment of the present disclosure. This figure shows the resultant amplified signal, which is the outputted modulated signal VA'.

FIG. 8 contains a graphical representation of outputted modulated signal VB in the time domain in accordance with at least one embodiment of the present disclosure. In this figure, the resultant demodulated signal, outputted modulated signal VB, is depicted.

FIG. 9 illustrates a graphical representation of outputted modulated signal Vout in the time domain in accordance with at least one embodiment of the present disclosure. This figure shows the resultant signal, outputted modulated signal Vout, after it has passed through an integrator.

FIG. 10 contains a graphical representation of the stimulation current (Istim) in the frequency domain in accordance with at least one embodiment of the present disclosure. In this figure, the stimulation current (Istim) signal 1010 is shown.

FIG. 11 shows a graphical representation of modulated signal V1 in the frequency domain in accordance with at least one embodiment of the present disclosure. In this figure, the signal of interest 1110 of modulated signal V1 has been modulated to a carrier frequency, "fchop". This frequency is chosen to be outside the bandwidth of typical aggressors, which include environmental noise.

10

15

20

25

30

FIG. 12 is a graphical representation of outputted modulated signal V2 in the frequency domain in accordance with at least one embodiment of the present disclosure. In this figure, it is evident that the modulated signal of interest 1210 of outputted modulated signal V2 has a lower signal amplitude than the modulated signal of interest 1110 of modulated signal V1, which is depicted in FIG. 11.

FIG. 13 contains a graphical representation of outputted modulated signal VA in the frequency domain in accordance with at least one embodiment of the present disclosure. This figure shows the inclusion of aggressors 1320 with the modulated signal of interest 1310 in outputted modulated signal VA.

FIG. 14 shows a graphical representation of outputted modulated signal VA' in the frequency domain in accordance with at least one embodiment of the present disclosure. In this figure, it is shown that the outputted modulated signal VA' has a modulated signal of interest 1410 that is amplified at a higher frequency than the aggressors 1420.

FIG. 15 illustrates a graphical representation of outputted modulated signal VB in the frequency domain in accordance with at least one embodiment of the present disclosure. This figure shows that outputted modulated signal VB has a signal of interest 1510 that is demodulated to a lower frequency and has aggressors 1520 that are modulated to a higher frequency. This figure also depicts the low pass filter of the integrator that outputted modulated signal VB will be passed through to produce outputted modulated signal Vout.

FIG. 16 is a graphical representation of outputted modulated signal Vout in the frequency domain in accordance with at least one embodiment of the present disclosure. In this figure, it is shown that the outputted modulated signal Vout has a signal of interest 1610 that is retained and aggressors 1620 that have been filtered out by an integrator acting as a low pass filter.

Although certain illustrative embodiments and methods have been disclosed herein, it can be apparent from the foregoing disclosure to those skilled in the art that variations and modifications of such embodiments and methods can be made without departing from the true spirit and scope of the art disclosed. Many other examples of the art disclosed exist, each differing from others in matters of detail only. Accordingly, it is

intended that the art disclosed shall be limited only to the extent required by the appended claims and the rules and principles of applicable law.

#### **WE CLAIM:**

5

10

- 1. A system for determining complex intercardiac impedance comprising: at least one electrode for propagating a modulated signal across a myocardium; at least one sensor for detecting an outputted modulated signal from the myocardium; and at least one circuit to reduce the influence of process noise (aggressors) in the outputted modulated signal, wherein the at least one circuit comprises:
- an amplifier for amplifying the outputted modulated signal to produce a second outputted modulated signal;
- a demodulator for demodulating the second outputted modulated signal to produce a third outputted modulated signal; and
- an integrator for passing the third outputted modulated signal through to produce a fourth outputted modulated signal,
- wherein amplitude and phase of the fourth outputted modulated signal indicate the complex impedance of the myocardium,
  - wherein changes in complex impedance patterns of the myocardium provide indication of various cardiac functions and an ischemic event.
- 2. The system of claim 1, wherein the system further comprises:

  means for providing an adjustable direct current signal, wherein the direct current signal is adjustable; and

  means for modulating the adjustable direct current signal to produce the modulated signal.
- 3. The system of claim 3, where the modulated signal has a nominal frequency of approximately 4 kilohertz to prevent interference with functions of other implanted devices.

10

20


25

- 4. The system of claim 2, wherein the system further comprises:
  a signal generator for generating a signal when the ischemic event is indicated,
  wherein the signal contains an alert message; and
  a transmitter for transmitting the signal.
- 5. The system of claim 2, wherein the system further comprises at least one implantable medical device (IMD).
- 6. The system of claim 5, wherein the at least one implantable medical device (IMD) is a cardiac pacemaker.
  - 7. The system of claim 5, wherein the at least one implantable medical device (IMD) is an implantable cardioverter defibrillator (ICD).
- 8. A system for determining complex intercardiac impedance comprising: at least one electrode means for propagating a modulated signal across a myocardium; at least one sensor means for detecting an outputted modulated signal from the myocardium; and
  - at least one circuit means for reducing the influence of process noise (aggressors) in the outputted modulated signal, wherein the at least one circuit means comprises: an amplifier means for amplifying the outputted modulated signal to produce a second outputted modulated signal;
  - a demodulator means for demodulating the second outputted modulated signal to produce a third outputted modulated signal; and
  - an integrator means for passing the third outputted modulated signal through to produce a fourth outputted modulated signal,
  - wherein amplitude and phase of the fourth outputted modulated signal indicate the complex impedance of the myocardium,
  - wherein changes in complex impedance patterns of the myocardium provide indication of various cardiac functions and an ischemic event.

10

15

- 9. The system of claim 8, wherein the system further comprises: means for providing an adjustable direct current signal, wherein the direct current signal is adjustable; and means for modulating the adjustable direct current signal to produce the modulated signal.
- 10. The system of claim 9, wherein the modulated signal has a nominal frequency of approximately 4 kilohertz to prevent interference with functions of other implanted devices.
- 11. The system of claim 9, wherein the system further comprises: a signal generator means for generating a signal when the ischemic event is indicated, wherein the signal contains an alert message; and a transmitter means for transmitting the signal.
- 12. The system of claim 9, wherein the system further comprises at least one implantable medical device (IMD).
- 13. The system of claim 12, wherein the at least one implantable medical device (IMD) is a cardiac pacemaker.



2/9







FIG. 2







4/9

FIG. 6








FIG. 7





5/9



















8/9

FIG. 15



9/9

FIG. 16



International application No PCT/US2009/058127

A. CLASSIFICATION OF SUBJECT MATTER INV. A61B5/053 G01R27/02 ADD. A61B5/026 A61N1/365

H03F3/00 A61N1/372

A61N1/39

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

 $\begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{A61B} & \mbox{A61N} & \mbox{G01R} & \mbox{H03F} \end{array}$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, INSPEC, BIOSIS, COMPENDEX, WPI Data

Category*	Citation of document, with indication, where appropriate, of t	he relevant passages	Relevant to claim No.	
X	US 7 391 257 B1 (DENISON TIMOT AL) 24 June 2008 (2008-06-24)	THY J [US] ET	1-3, 5-10, 12-13	
Y	column 1, lines 13-24 column 6, lines 18-41 column 7, lines 28-30 column 8, lines 45-51 column 11, lines 36-38 figure 2		4,11	
<b>X</b>	US 7 385 443 B1 (DENISON TIMOT 10 June 2008 (2008-06-10)	THY J [US])	1-3, 5-10, 12-13	
Y	column 1 - column 12; figure 2	2	4,11	
		-/		
X Furt	her documents are listed in the continuation of Box C.	X See patent family annex.		
* Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier document but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family		
Date of the	actual completion of the international search	Date of mailing of the international sea	rch report	
1	4 January 2010	25/01/2010		
Name and I	mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Riiswiik	Authorized officer	11	

International application No
PCT/US2009/058127

Citation of document, with indication, where appropriate, of the relevant passages  US 2008/180278 A1 (DENISON TIMOTHY J [US])	Relevant to claim No.
US 2008/180278 A1 (DENISON TIMOTHY J [US])	neievant to claim No.
	1-3,
31 July 2008 (2008-07-31)	5-10, 12-13
column 1 - column 12; figure 2	4,11
17 January 2008 (2008-01-17)	4,11
	1
WO 2009/042172 A2 (MEDTRONIC INC [US];	1-3, 5-10, 12-13
WO 2009/042313 A1 (MEDTRONIC INC [US]; DENISON TIMOTHY J [US]; HEINKS MICHAEL W [US]; AND) 2 April 2009 (2009-04-02) page 1 - page 15	1-3, 5-10, 12-13
MART MIN ET AL: "Electrical Impedance and Cardiac Monitoring Technology, Potential and Applications" INTERNATIONAL JOURNAL OF BIOELECTROMAGNETISM, INTERNATIONAL SOCIETY FOR BIOELECTROMAGNETISM, TAMPERE, FI, vol. 5, no. 1, 1 January 2003 (2003-01-01), pages 53-56, XP009127922 ISSN: 1456-7857 the whole document	1-13
US 2008/269631 A1 (DENISON TIMOTHY J [US] ET AL) 30 October 2008 (2008-10-30) the whole document	1–13
US 2008/269630 A1 (DENISON TIMOTHY J [US] ET AL) 30 October 2008 (2008-10-30) the whole document	1-13
BROWN D A ET AL: "Myocardial Electrical Impedance Responds to Ischemia and Reperfusion in Humans" IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, IEEE SERVICE CENTER, PISCATAWAY, NJ, US, vol. 51, no. 12, 1 December 2004 (2004-12-01), pages 2206-2209, XP011122310 ISSN: 0018-9294 the whole document	1-13
	wo 2009/042172 A2 (MEDTRONIC INC [US]; DENISON TIMOTHY J [US]; JENSEN RANDY M [US]; SANTA) 2 April 2009 (2009-04-02) paragraphs [0002], [0 41], [0 77] - [0079], [184]  WO 2009/042313 A1 (MEDTRONIC INC [US]; DENISON TIMOTHY J [US]; HEINKS MICHAEL W [US]; AND) 2 April 2009 (2009-04-02) page 1 - page 15  MART MIN ET AL: "Electrical Impedance and Cardiac Monitoring Technology, Potential and Applications" INTERNATIONAL JOURNAL OF BIOELECTROMAGNETISM, INTERNATIONAL SOCIETY FOR BIOELECTROMAGNETISM, TAMPERE, FI, vol. 5, no. 1, 1 January 2003 (2003-01-01), pages 53-56, XP009127922 ISSN: 1456-7857 the whole document  US 2008/269631 A1 (DENISON TIMOTHY J [US] ET AL) 30 October 2008 (2008-10-30) the whole document  US 2008/269630 A1 (DENISON TIMOTHY J [US] ET AL) 30 October 2008 (2008-10-30) the whole document  US 2008/269630 N (DENISON TIMOTHY J [US] ET AL) 30 October 2008 (2008-10-30) the whole document  US 2008/269630 A1 (DENISON TIMOTHY J [US] ET AL) 30 October 2008 (2008-10-30) the Whole document  US 2008/269630 A1 (DENISON TIMOTHY J [US] ET AL) 30 October 2008 (2008-10-30) the Whole document  US 2008/269630 A1 (DENISON TIMOTHY J [US] ET AL) 30 October 2008 (2008-10-30) the Whole document  US 2008/269630 A1 (DENISON TIMOTHY J [US] ET AL) 30 October 2008 (2008-10-30) the Whole document

International application No
PCT/US2009/058127

Continue	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	PCT/US2009	19/05812/				
Category*	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.				
	DUNN R M ET AL: "Algorithm for tissue ischemia estimation based on electrical impedance spectroscopy" IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, IEEE SERVICE CENTER, PISCATAWAY, NJ, US, vol. 50, no. 12, 1 December 2003 (2003-12-01), pages 1352-1359, XP011103662 ISSN: 0018-9294 the whole document						
	<del></del>						
	•						
		<u> </u>					
			•				
	·						
			- !				
			· · · · · · · · · · · · · · · · · · ·				
			1				

Information on patent family members

International application No PCT/US2009/058127

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 7391257	B1	24-06-2008	CN	101589548		25-11-2009
			EP	2119000		18-11-2009
			US	2008183098		31-07-2008
			WO	2008094269	A1	07-08-2008
US 7385443	B1	10-06-2008	AU	2007345667	A1	07-08-2008
			CA	2675382		07-08-2008
		,	CN	101589549		25-11-2009
			EP	2127072		02-12-2009
			US	2008211574		04-09-2008
			WO	2008094271	A1	07-08-2008
US 2008180278	A1	31-07-2008	EP	2127073	A1	02-12-2009
			WO	2008094270	A1	. 07-08-2008
US 2008015659	A1	17-01-2008	WO	2009042030	A2	02-04-2009
WO 2009042172	A2	02-04-2009	US	2009082691	A1	26-03-2009
WO 2009042313	A1	02-04-2009	US	2009079607	A1	26-03-2009
US 2008269631	A1	30-10-2008	NONE	-		
US 2008269630	A1	30-10-2008	NONE	<del>-</del>		